Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hughes

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|March 8, 2014
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infectionHiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Hepatology International|February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label studyMark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
Science (New York, N.Y.)|February 2, 2023
The NIH-led research response to COVID-19Francis Collins, Stacey Adam, Christine Colvis, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Liver International : Official Journal of the International Association for the Study of the Liver|December 20, 2015
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysisJia-Horng Kao, Donald M Jensen, Michael P Manns, et al.
Hepatology (Baltimore, Md.)|March 8, 2014
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infectionHiromitsu Kumada, Yoshiyuki Suzuki, Kenji Ikeda, et al.
Journal of Hepatology|February 24, 2015
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-respondersDonald Jensen, Kenneth E Sherman, Christophe Hézode, et al.
Hepatology International|February 18, 2017
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label studyMark S Sulkowski, Walford J Fessel, Adriano Lazzarin, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
Lancet (London, England)|August 1, 2014
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort studyMichael Manns, Stanislas Pol, Ira M Jacobson, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
JAMA|May 6, 2015
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infectionFred Poordad, William Sievert, Lindsay Mollison, et al.
Science (New York, N.Y.)|February 2, 2023
The NIH-led research response to COVID-19Francis Collins, Stacey Adam, Christine Colvis, et al.
Pageof 5